GE, Roche to partner on digital diagnostics platform

Last updated: 12-07-2018

Read original article here

GE, Roche to partner on digital diagnostics platform

GE Healthcare and Roche are working together on an effort to develop and co-market clinical decision support solutions for the healthcare industry, entering a long-term strategic partnership.

Chicago-based GE Healthcare and Switzerland-based Roche say they plan to develop a digital platform that will enable the use of analytics to provide workflow solutions and apps that support clinicians who are making clinical decisions.

The initiative aims to allow the integration and analysis of a variety of data, patient records and images to enable better decision making by clinicians, the partners say. They also aim to include in-vivo and in-vitro data, medical best practices, real-time monitoring and recent research to support clinicians making decisions on treatment for patients.

The companies say they plan to develop jointly branded clinical decision support software that will enable accurate clinical decisions to be made earlier through quicker diagnosis of patients. The partnership will apply advanced analytics to in-vivo data from GE’s medical imaging and monitoring equipment with in-vitro data from Roche’s biomarker, tissue pathology, genomics and sequencing products.

Also See: FDA issues draft guidance on clinical decision support software

For example, oncology care teams will have a comprehensive data dashboard to review, collaborate and determine treatment decisions for cancer patients at each stage of their disease. In the critical care setting, data from a patient’s hospital monitoring equipment could be integrated with their biomarker, tissue pathology, genomic and sequencing data, helping physicians to identify, or even predict severe complications before they strike.

GE Healthcare, a subsidiary of GE, reported $18 billion in sales in 2017 with a significant position in medical imaging equipment. Roche Diagnostics has long delivered in-vitro diagnostic solutions to the healthcare industry.

“This is the first time that two major players in healthcare have combined advanced analytics with in-vivo and in-vitro diagnostics to this degree,” said Kieran Murphy, president and CEO of GE Healthcare. “This alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry.”

“This unique partnership will deliver innovative solutions and insights in clinical decision-making,” says Roland Diggelmann, CEO of Roche Diagnostics, a subsidiary of the Roche Group. “Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings.”


Read the rest of this article here